Home » Stocks » CSII

Cardiovascular Systems, Inc. (CSII)

Stock Price: $34.41 USD -1.06 (-2.97%)
Updated May 10, 2021 4:00 PM EDT - Market closed
After-hours: $34.59 +0.18 (0.52%) May 10, 4:04 PM
Market Cap 1.39B
Revenue (ttm) 230.53M
Net Income (ttm) -23.30M
Shares Out 38.91M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $34.41
Previous Close $35.47
Change ($) -1.06
Change (%) -2.97%
Day's Open 35.55
Day's Range 34.07 - 35.47
Day's Volume 267,915
52-Week Range 27.70 - 48.28

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -50.00% and -0.25%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q3 Earnings Release

4 days ago - Business Wire

ST. PAUL, Minn.--(BUSINESS WIRE)--JOURNAL OF MEDICAL ECONOMICS ARTICLE DEMONSTRATES ECONOMIC BENEFITS OF CARDIOVASCULAR SYSTEMS ORBITAL ATHERECTOMY

1 week ago - Business Wire

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients wit...

1 week ago - Business Wire

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 third-quarter conference call on Thursday, May 6, 2021, at 3:30 p.m. CT (...

3 weeks ago - Business Wire

Cardiovascular Systems' (CSII) investment in CarePICS will advance patient access to the suitable treatment at the right time, thereby leading to improved care and reduced amputations.

1 month ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES INVESTMENT AND ACQUISITION OPTION AGREEMENT WITH TELEHEALTH COMPANY, CAREPICS, LLC

1 month ago - Business Wire

Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.

Other stocks mentioned: ABT, HOLX, HRC, IDXX, LH, LMAT
1 month ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PARTICIPATE AT THE 20TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE

1 month ago - Business Wire

Cardiovascular Systems' (CSII) acquisition of Peripheral Support Catheters will enhance outcomes for patients undergoing complex peripheral and coronary interventions.

1 month ago - Zacks Investment Research

Cardiovascular Systems' (CSII) WIRION demonstrated a major adverse event rate of 1.9%, which is lower than the earlier reported rates for other lower extremity embolic protection filters.

1 month ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--WIRION

1 month ago - Business Wire

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--CSII Q3 Conferences

2 months ago - Business Wire

Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.

3 months ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--First patient treated in Europe

3 months ago - Business Wire

Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.

3 months ago - Zacks Investment Research

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 100.00% and -1.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Cardiovascular Systems (NASDAQ:CSII) were unchanged in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 100.00% year over year to ($0....

3 months ago - Benzinga

ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q2 Financial Results

3 months ago - Business Wire

ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q2 Financial Results

3 months ago - Business Wire

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES PARTNERSHIP WITH CHANSU VASCULAR TECHOLOGIES, LLC TO DEVELOP NEW DRUG-COATED BALLOON TECHNOLOGY

3 months ago - Business Wire

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES SACHIN H. JAIN, MD, MBA, JOINS BOARD OF DIRECTORS

3 months ago - Business Wire

Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.

3 months ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. RECEIVES CE MARK FOR DIAMONDBACK 360® CORONARY ORBITAL ATHERECTOMY SYSTEM

3 months ago - Business Wire

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO WEBCAST FISCAL 2021 SECOND-QUARTER EARNINGS CONFERENCE CALL WEDNESDAY, FEBRUARY 3

3 months ago - Business Wire

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PRESENT AT THE 23RD ANNUAL NEEDHAM VIRTUAL GROWTH CONFERENCE

4 months ago - Business Wire

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PRESENT AT THE STIFEL 2020 VIRTUAL HEALTHCARE CONFERENCE

5 months ago - Business Wire

Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.

6 months ago - Zacks Investment Research

Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q1 2021 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 78.26% and 7.59%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2021 FIRST-QUARTER FINANCIAL RESULTS

6 months ago - Business Wire

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 first-quarter conference call on Wednesday, November 4, 2020, at 3:30 p.m...

6 months ago - Business Wire

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients wit...

6 months ago - Business Wire

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients wit...

7 months ago - Business Wire

Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.

7 months ago - Zacks Investment Research

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC.

8 months ago - Business Wire

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.

8 months ago - Zacks Investment Research

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q2 earnings as patients avoid hospitals.

9 months ago - Zacks Investment Research

Cardiovascular Systems' (CSII) CEO Scott Ward on Q4 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 2.27% and 10.49%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC.

9 months ago - Business Wire

Cardiovascular Systems (NASDAQ: CSII) releases its next round of earnings this Tuesday, August 04.

9 months ago - Benzinga

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS PRESENTS REACH PVI STUDY AT THE NEW CARDIOVASCULAR HORIZONS CONFERENCE

9 months ago - Business Wire

The market is reacting to the company's decision to initiate a public offering of common stock.

11 months ago - The Motley Fool

About CSII

Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coro... [Read more...]

Industry
Medical Devices
IPO Date
Feb 26, 2009
CEO
David Martin
Employees
779
Stock Exchange
NASDAQ
Ticker Symbol
CSII
Full Company Profile

Financial Performance

In 2020, CSII's revenue was $236.55 million, a decrease of -4.63% compared to the previous year's $248.02 million. Losses were -$27.24 million, 10,580.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for CSII stock is "Buy." The 12-month stock price forecast is 46.38, which is an increase of 34.79% from the latest price.

Price Target
$46.38
(34.79% upside)
Analyst Consensus: Buy